Redesigner drugs.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 15286643.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Drug development is a risky business, and the final product can have serious, sometimes deadly flaws. But by focusing on fixing those flaws, companies are catapulting themselves to profitability.
Medical subject headings
- Drug Delivery Systems
- Drug Design
- Drug Industry
- Drug Therapy
- Pharmaceutical Preparations